



BETA DRUGS LIMITED

BDL/PKL/SEC/2023

7th November, 2023

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub.: Outcome of the Board Meeting-Written off Investment in Beta Ubk International Private Limited by Beta Drugs Limited

Ref.: Intimation under Regulation 30 and other applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR")

Dear Sir/Madam,

In terms of Regulation 30 of SEBI LODR, this is to inform you that the Board of Directors of the Company at its meeting held on 7th November, 2023, inter alia, has considered and approved to write off the investment made by the company total amounting 88,000 US Dollars in Beta Ubk. International Private Limited.

Beta Ubk. International Private Limited will cease to be a subsidiary of the Company. The company continues its operations of Sales & Marketing in Uzbekistan through its own sales team from India. All the MA's (Marketing Authorizations) belong to Beta Drugs Limited, India.

The Meeting commenced at 10.00 a.m. and concluded at 4.15 p.m.

Kindly take the above on your record.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com